Ras Signaling Pathway as a Novel Downstream Effector of Bet Inhibitors in Subduing Diffuse Large B-Cell Lymphoma Migration and Progression

Project: National Science and Technology CouncilNational Science and Technology Council Academic Grants

Project Details

Abstract

雖然免疫化學療法對於瀰漫性大B細胞淋巴瘤(DLBCL)的治療效果顯著,但疾病的高度異質性造成治療的預後與反應難以預測,即便現今有多種亞型分類法,在臨床反應上依然顯示有更精確亞型的存在。我們過去的研究揭示BETi透過STAT3抑制癌細胞擴散,也發現了RAS訊息做為BET抑制劑調控DLBCL移行及進展之新機轉,另外,我們也將透過基因體與蛋白質體的全方面研究,探討優化疾病亞型分類的可能性。若本計畫執行順利,將提供臨床醫學以下重要訊息:找出RAS訊息活化的DLBCL亞型,並揭示其潛在的預後意義;(2) BETi協同降低RAS訊息對於治療特定亞型的可行性; (3) DLBCL亞型驅策的個體化的治療設計。

Project IDs

Project ID:PC11007-2458
External Project ID:MOST109-2314-B182-064-MY3
StatusFinished
Effective start/end date01/08/2131/07/22

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.